In June 2010, we entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix and all next-generation gonadotropin-releasing hormone (GnRH) antagonists (collectively, GnRH Compounds) for women’s and men’s health. Under the terms of our agreement with AbbVie, we and AbbVie will work jointly to advance GnRH Compounds towards commercialization. AbbVie is responsible for all development, marketing, and commercialization costs and will be entitled to a percentage of worldwide sales of GnRH Compounds.
Mitsubishi Tanabe Pharma
In March 2015, Neurocrine entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of NBI-98854 in Japan and other select Asian markets.
Under the terms of the agreement, Mitsubishi Tanabe intends to initially develop NBI-98854 in Japan for the chorea associated with Huntington’s disease and tardive dyskinesia. Neurocrine will support Mitsubishi Tanabe’s initial clinical efforts in developing NBI-98854, thereafter Mitsubishi Tanabe will be responsible for all development, marketing, and commercialization costs in their territories and Neurocrine will be entitled to a percentage of sales by Mitsubishi Tanabe. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.
On February 9, 2017, we entered into an exclusive licensing agreement with BIAL for the development and commercialization of opicapone in the United States and Canada. Opicapone is a once-daily, peripherally-acting, highly-selective COMT inhibitor that was approved in June 2016 by the European Commission as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Under the terms of the agreement, we are responsible for the management and cost of all opicapone development and commercialization activities. We intend to meet with the FDA during 2017 to discuss a potential NDA submission for opicapone.